Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.

Pediatric blood & cancer - 1 Sept 2023

Cooper Todd M, Alonzo Todd A, Tasian Sarah K, Kutny Matthew A, Hitzler Johann, Pollard Jessica A, Aplenc Richard, Meshinchi Soheil, Kolb E Anders

Abstract excerpt

During the past decade, the outcomes of pediatric patients with acute myeloid leukemia (AML) have plateaued with 5-year event-free survival (EFS) and overall survival (OS) of approximately 46 and 64%, respectively. Outcomes are particularly poor for those children with high-risk disease, who have 5-year OS of 46%. Substantial survival improvements have been observed for a subset of patients treated with targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Child

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 37480164
DOI: 10.1002/pbc.30584
PMCID: PMC10614720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.PMID 37480164Read ↗

Treatment Approaches in Pediatric Acute Myeloid Leukemia: A Narrative ReviewSemantic proximity Read ↗

Treatment of acute myeloid leukemia in children: A practical perspective.Semantic proximity Read ↗

A Review in Childhood Acute Myeloid Leukemia: Diagnosis and Novel TreatmentSemantic proximity Read ↗

Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Semantic proximity Read ↗

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.Semantic proximity Read ↗

Children’s Oncology Group’s 2023 Blueprint for Research: Cellular Therapy and Stem Cell TransplantationSemantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

Pediatric acute leukemia therapies informed by molecular analysis of high-risk disease.Semantic proximity Read ↗

Children’s Oncology Group Blueprint for Research: Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Novel classification system and high-risk categories of pediatric acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Semantic proximity Read ↗

How to improve AML outcomes?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.